Abridge was founded in 2018 with the mission of powering deeper understanding in healthcare. Our AI-powered platform was purpose-built for medical conversations, improving clinical documentation efficiencies while enabling clinicians to focus on what matters most—their patients. Our enterprise-grade technology transforms patient-clinician conversations into structured clinical notes in real-time, with deep EMR integrations. Powered by Linked Evidence and our purpose-built, auditable AI, we are the only company that maps AI-generated summaries to ground truth, helping providers quickly trust and verify the output. As pioneers in generative AI for healthcare, we are setting the industry standards for the responsible deployment of AI across health systems.
Acelab is an all-in-one platform designed for architects and designers to research, specify, and manage building materials efficiently. The platform utilizes AI-driven tools to help users find the right products quickly, generate detailed comparisons, and manage project documentation seamlessly. Acelab differentiates itself by offering a free service for architects while providing manufacturers with subscription-based branding options. With over 15,000 firms trusting the platform, Acelab is positioned as a leading resource in the architecture and construction industry, streamlining the materials decision-making process and enhancing collaboration among project teams.
Asimov is a synthetic biology company that provides an integrated suite of cells, genes, and software to enable advanced genetic design and manufacture of therapies. Their platform includes engineered host cells, a genetic parts library, and cloud-based design software, allowing clients to develop custom cell lines and optimize genetic constructs. Asimov differentiates itself through its comprehensive approach, combining synthetic biology with computational tools, and has achieved significant traction with partnerships across the biotech industry, including over 25 companies from small biotechs to large pharmaceutical firms. The company is positioned at the forefront of the synthetic biology market, leveraging AI and machine learning to enhance genetic engineering capabilities.